GalNAc

N-acetylgalactosamine (GalNAc) is a ligand widely used for hepatocyte-targeted delivery of oligonucleotide therapeutics. GalNAc conjugates typically employ a triantennary structure that binds with high affinity to the asialoglycoprotein receptor (ASGPR) expressed on hepatocytes. After receptor recognition, the conjugate is internalized through receptor-mediated endocytosis, allowing efficient uptake of siRNA or antisense oligonucleotides by liver cells. This targeted delivery strategy significantly enhances intracellular exposure while reducing systemic distribution.

GalNAc conjugation has become a leading delivery strategy for liver-targeted RNA therapeutics due to its high specificity, favorable pharmacokinetics, and convenient subcutaneous dosing. The platform enables potent gene silencing with lower doses and improved safety profiles. With multiple approved therapies and an expanding pipeline, GalNAc technology continues to support the development of next-generation oligonucleotide drugs for metabolic, genetic, and rare liver diseases.

Liste des produits

N° catalogue	Nom	N° CAS	M.M.
CH52001	Tri-b-GalNAc-C12-alkyne
CH52002	Tri-b-GalNAc-C12-amido-C3-azide
CH52003	Tri-b-GalNAc-gly-C6-DBCO
CH52004	GalNAc Cluster Amide C7 Linker DMT Succinate LCAA CPG 1000 A
CH52005	TEG-GalNAc Cluster Succinate CPG (1000 A)
CH52006	TEG-GalNAc Cluster Amidite
CH52007	Peracetylated GalNAc PEG linker-Azide
CH52008	Peracetylated GalNAc PEG linker-Amino
CH52009	alpha-D-GalNAc-PEG3-Biotin
CH52010	alpha-GalNAc-PEG3-Amine	267227-84-9	352.38

Nous contacter

Connectez votre projet à une équipe chimique pratique

De l’évaluation de voie au développement de procédé et au scale-up, CHEMOS soutient la synthèse à façon avec expérience R&D et base de production.